Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Standard
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. / Nitzsche, B; Gloesenkamp, C; Schrader, M; Hoffmann, B; Zengerling, F; Balabanov, S; Honecker, Friedemann; Höpfner, M.
In: BRIT J CANCER, Vol. 107, No. 11, 11, 2012, p. 1853-1863.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
AU - Nitzsche, B
AU - Gloesenkamp, C
AU - Schrader, M
AU - Hoffmann, B
AU - Zengerling, F
AU - Balabanov, S
AU - Honecker, Friedemann
AU - Höpfner, M
PY - 2012
Y1 - 2012
N2 - Resistance to cisplatin-based chemotherapy is associated with poor prognosis in testicular germ cell cancer, emphasising the need for new therapeutic approaches. In this respect, the therapeutic concept of anti-angiogenesis is of particular interest. In a previous study, we presented two novel anti-angiogenic compounds, HP-2 and HP-14, blocking the tyrosine kinase activity of angiogenic growth factor receptors, such as vascular endothelial growth factor receptor-2 (VEGFR-2), and related signalling pathways in testicular cancer. In this study, we investigated the efficacy of these new compounds in platinum-resistant testicular germ cell tumours (TGCTs), in vitro and in vivo.
AB - Resistance to cisplatin-based chemotherapy is associated with poor prognosis in testicular germ cell cancer, emphasising the need for new therapeutic approaches. In this respect, the therapeutic concept of anti-angiogenesis is of particular interest. In a previous study, we presented two novel anti-angiogenic compounds, HP-2 and HP-14, blocking the tyrosine kinase activity of angiogenic growth factor receptors, such as vascular endothelial growth factor receptor-2 (VEGFR-2), and related signalling pathways in testicular cancer. In this study, we investigated the efficacy of these new compounds in platinum-resistant testicular germ cell tumours (TGCTs), in vitro and in vivo.
KW - Animals
KW - Humans
KW - Male
KW - Cell Line, Tumor
KW - Gene Expression Profiling
KW - Drug Resistance, Neoplasm
KW - Cell Cycle/drug effects
KW - Cisplatin/therapeutic use
KW - Antineoplastic Agents/pharmacology
KW - Chick Embryo
KW - Angiogenesis Inhibitors/pharmacology
KW - Neoplasms, Germ Cell and Embryonal/drug therapy/pathology
KW - Neovascularization, Pathologic/drug therapy
KW - Testicular Neoplasms/drug therapy/pathology
KW - Vascular Endothelial Growth Factor Receptor-2/analysis
KW - Animals
KW - Humans
KW - Male
KW - Cell Line, Tumor
KW - Gene Expression Profiling
KW - Drug Resistance, Neoplasm
KW - Cell Cycle/drug effects
KW - Cisplatin/therapeutic use
KW - Antineoplastic Agents/pharmacology
KW - Chick Embryo
KW - Angiogenesis Inhibitors/pharmacology
KW - Neoplasms, Germ Cell and Embryonal/drug therapy/pathology
KW - Neovascularization, Pathologic/drug therapy
KW - Testicular Neoplasms/drug therapy/pathology
KW - Vascular Endothelial Growth Factor Receptor-2/analysis
M3 - SCORING: Journal article
VL - 107
SP - 1853
EP - 1863
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 11
M1 - 11
ER -
